Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 5/20 | 0.36 |
| ▸ | TDO2 | P48775 | 10/20 | 0.36 |
| ▸ | IDO1 | P14902 | 5/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.34 |
| ▸ | SGK1 | O00141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23478156 | 0.85 | LMNA (0.41) | EPAS1TDO2IDO1 | |
| SCHEMBL23478343 | 0.84 | IDO1 (0.39) | EPAS1TDO2IDO1 | |
| SCHEMBL29981228 | 0.81 | IDO1 (0.43) | EPAS1TDO2IDO1 | |
| SCHEMBL23478340 | 0.81 | IDO1 (0.43) | EPAS1TDO2IDO1 | |
| SCHEMBL29980738 | 0.79 | PLK4 (0.41) | EPAS1TDO2IDO1 | |
| SCHEMBL23478370 | 0.79 | PLK4 (0.41) | EPAS1TDO2IDO1 | |
| SCHEMBL23461416 | 0.78 | KDM4E (0.40) | EPAS1TDO2IDO1 | |
| SCHEMBL23478762 | 0.77 | EPAS1 (0.41) | EPAS1 | |
| SCHEMBL29780231 | 0.77 | EPAS1 (0.41) | EPAS1 | |
| SCHEMBL23478324 | 0.77 | HDAC3 (0.42) | EPAS1TDO2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024438-A1 | INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| CN-114760994-A | Inhibitors of HIF-2 alpha | 艾库斯生物科学有限公司 | 2022-07-15 | — | — | CN | disclosed |
| WO-2021113436-A1 | INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024438-A1 | INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | EPAS1 9/4885TDO2 1927/4885IDO1 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.